Platelet Rich Plasma In Arthroscopic Rotator Cuff Repair: A Prospective Rct Study, 2-Year Follow-Up

Department of Scienze Medico Chirurgiche, University of Milano, IRCCS Policlinico San Donato, Milano, Italy.
Journal of shoulder and elbow surgery / American Shoulder and Elbow Surgeons ... [et al.] (Impact Factor: 2.29). 06/2011; 20(4):518-28. DOI: 10.1016/j.jse.2011.02.008
Source: PubMed


Local application of autologous platelet rich plasma (PRP) improves tendon healing in patients undergoing arthroscopic rotator cuff repair. Study design: Prospective, randomized, controlled, double blind study; considering an alpha level of 5%, a power of 80%, 22 patients for group are needed.
Fifty-three patients who underwent shoulder arthroscopy for the repair of a complete rotator cuff tear were randomly divided into 2 groups, using a block randomization procedure. A treatment group (N = 26) consisted of those who received an intraoperative application of PRP in combination with an autologous thrombin component. A control group (N = 27) consisted of those who did not receive that treatment. Patients were evaluated with validated outcome scores. A magnetic resonance image (MRI) was performed in all cases at more than 1 year post-op. All patients had the same accelerated rehabilitation protocol.
The 2 groups were homogeneous. The pain score in the treatment group was lower than the control group at 3, 7, 14, and 30 days after surgery (P < .05). On the Simple Shoulder Test (SST), University of California (UCLA), and Constant scores, strength in external rotation, as measured by a dynamometer, were significantly higher in the treatment group than the control group at 3 months after surgery (strength in external rotation [SER]: 3 ± 1.6 vs 2.1 ± 1.3 kg; SST: 8.9 ± 2.2 vs 7.1 ± 2.7; UCLA: 26.9 ± 3 vs 24.2 ± 4.9; Constant: 65 ± 9 vs 57.8 ± 11; P < .05). There was no difference between the 2 groups after 6, 12, and 24 months. The follow-up MRI showed no significant difference in the healing rate of the rotator cuff tear. In the subgroup of grade 1 and 2 tears, with less retraction, SER in the PRP group was significant higher at 3, 6, 12, and 24 months postoperative (P < .05).
The results of our study showed autologous PRP reduced pain in the first postoperative months. The long-term results of subgroups of grade 1 and 2 tears suggest that PRP positively affected cuff rotator healing.

51 Reads
  • Source
    • "Five studies assessed the effects of PRP therapy combined with rotator cuff repair. A 2011 randomized trial compared 26 patients managed with an intraoperative application of PRP and 27 managed without PRP [44]. Pain scores were significantly lower in the PRP group during the first postoperative month. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although tendinopathies constitute a heterogeneous group of conditions, they are often treated by similar combinations of local and systemic symptomatic interventions. The vast number of causes, pathophysiological mechanisms, and histological changes that characterizes tendinopathies may explain that the standard treatment fails in some patients. Platelet-rich plasma (PRP), which contains a host of soluble mediators including growth factors, has been suggested as a second-line treatment for refractory tendinopathy, with the goal of expediting tendon healing or remodeling. Here, we report a systematic literature review of basic research data from humans and animals that support the clinical use of PRP in tendinopathies and of clinical studies in the most common tendinopathies (elbow, knee, shoulder, and Achilles tendon). Our objective is to clarify the role for this new injectable treatment, which is garnering increasing attention. The level of evidence remains low, as few well-designed randomized controlled trials have been published. The available scientific evidence does not warrant the use of PRP for the first-line treatment of tendinopathy. PRP therapy may deserve consideration in specific tendinopathy subtypes, after failure of ultrasound-guided corticosteroid injections. Nevertheless, further studies are needed to define these potential indications and the optimal treatment protocols. A key point is that the complexity of the tendon healing process cannot be replicated simply by injecting a subset of growth factors, whose effects may occur in opposite directions over time. Topics not discussed in this review are the regulatory framework for PRP therapy, PRP nomenclature, and precautions for use, which are described in a previous article (Does platelet-rich plasma have a role in the treatment of osteoarthritis, Ornetti P, et al. [1]). Copyright © 2015 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
    Joint, bone, spine: revue du rhumatisme 04/2015; 82(4). DOI:10.1016/j.jbspin.2015.02.004 · 2.90 Impact Factor
  • Source
    • "Cinq études se sont intéressées à l'utilisation du PRP après réparation de la coiffe des rotateurs. La première a été publiée par Randelli et al. en 2011 [43]. Il s'agissait d'une étude prospective randomisée incluant 26 patients avec injections de PRP et 27 patients sans injection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Les tendinopathies constituent un groupe nosologique hétérogène fréquemment traité univoquement par l’association de thérapeutiques symptomatiques locales et générales. La grande diversité de leurs étiologies, de leurs physiopathologies et de leurs modifications histologiques peuvent expliquer certains échecs des traitements habituels. L’utilisation dans le traitement des tendinopathies des concentrés plaquettaires (PRP) contenant de nombreux médiateurs solubles dont des facteurs de croissance est parfois proposée en seconde intention dans des formes rebelles afin d’accélérer la cicatrisation ou le remodelage. Cette revue de la littérature rapporte d’abord les données fondamentales aussi bien chez l’homme que chez l’animal soutenant l’utilisation clinique des PRP dans les tendinopathies puis les résultats des études cliniques dans les tendinopathies les plus communes (les tendinopathies du coude, du genou, de l’épaule ou d’Achille) pour mieux cerner la place de cette nouvelle thérapeutique injectable, en plein essor actuellement. Les niveaux de preuve restent faibles avec peu d’études randomisées contrôlées sans faiblesse méthodologique. À l’heure actuelle, aucune donnée scientifique ne justifie l’utilisation des concentrés plaquettaires type PRP dans le traitement de première intention des tendinopathies. Cette thérapeutique pourrait se discuter dans certains sous-types de lésions tendineuses, après échec des traitements habituels sous la forme d’infiltrations écho-guidées mais ces indications restent à être mieux précisées et les protocoles thérapeutiques à mieux définir. En tout état de cause, la complexité du phénomène de cicatrisation tendineuse ne peut se résumer à une injection de certains facteurs de croissance dont les effets pourraient parfois s’opposer dans le temps.
    Revue du Rhumatisme 01/2015; 82(2). DOI:10.1016/j.rhum.2014.12.001
  • Source
    • "Beneficial effects by clinical use of PRP were seen in treatment of rotator cuff tears [9], Achilles tendon ruptures [22], chronic tendinosis [23], muscle injuries [7], ACL-rupture [12], and cartilage defects [11, 24]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Meniscal lesions in the avascular zone are still a problem in traumatology. Tissue Engineering approaches with mesenchymal stem cells (MSCs) showed successful regeneration of meniscal defects in the avascular zone. However, in daily clinical practice, a single stage regenerative treatment would be preferable for meniscus injuries. In particular, clinically applicable bioactive substances or isolated growth factors like platelet-rich plasma (PRP) or bone morphogenic protein 7 (BMP7) are in the focus of interest. In this study, the effects of PRP and BMP7 on the regeneration of avascular meniscal defects were evaluated. In vitro analysis showed that PRP secretes multiple growth factors over a period of 8 days. BMP7 enhances the collagen II deposition in an aggregate culture model of MSCs. However applied to meniscal defects PRP or BMP7 in combination with a hyaluronan collagen composite matrix failed to significantly improve meniscus healing in the avascular zone in a rabbit model after 3 months. Further information of the repair mechanism at the defect site is needed to develop special release systems or carriers for the appropriate application of growth factors to support biological augmentation of meniscus regeneration.
    BioMed Research International 08/2014; 2014:537686. DOI:10.1155/2014/537686 · 2.71 Impact Factor
Show more

Similar Publications